Long acting GLP-1 receptor agonist (injectable)
Taspoglutide 5 mg injection once weekly
TASP_SC_5MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.68 (0.01 to 43.65) | 0.43 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.66 (1.15 to 5.92) | 0.50 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.46 (0.24 to 6.04) | 0.66 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.09 (0.29 to 3.32) | 0.65 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.86 (0.05 to 14.28) | 0.47 |